In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Researchers discover molecular basis for increased cardiovascular disease in older women

Older women in the study had mitochondrial dysfunction, reduced antioxidant proteins, and increased inflammation

Basic Science
Cardiac Diseases


Vienna, Austria – 21 April 2018: Researchers have discovered the molecular basis for the increased incidence of cardiovascular diseases in older women. The study, which is presented today at Frontiers in CardioVascular Biology (FCVB) 2018, a European Society of Cardiology (ESC) congress found that older women had mitochondrial dysfunction, reduced antioxidant proteins, and increased inflammation. (1))

Previous studies have shown sex differences in the age at which cardiovascular diseases occur. Ischaemic heart disease, for example, develops on average seven to ten years later in women compared with men. It occurs three to four times more often in men than in women below the age of 60 years, but after the age of 75, most patients are women. (2)

It is not clear why many women are protected from cardiovascular disease at a young age but are more susceptible after menopause. Oestrogen levels may play a role but the mechanism is unknown. This study looked at molecular changes in the cells of the heart that happen with ageing, and how they differ between men and women.

Specifically, the researchers looked at healthy hearts to see if there are sex differences in mitochondrial function and inflammation during ageing. Heart tissue was obtained from seven women and seven men aged 17 to 40 years, and from eight women and nine men aged 50 to 68 years. The researchers measured levels of proteins involved in inflammation and in the function of the mitochondria.

The researchers found that the levels of Sirt1, a protein which is important for the function of the mitochondria, are higher in young women compared to young men. In the older hearts, Sirt1 levels had decreased in women but not in men. Expression of superoxide dismutase 2, an antioxidant protein in the mitochondria, was higher in young females than males but the difference was no longer present with age.

In addition, the expression of catalase, an enzyme that protects cells from oxidative damage, was higher in young females than males but again the difference was lost with age.

With age, female hearts shifted from an anti-inflammatory to a pro-inflammatory environment. Compared to young men, young women had higher levels of anti-inflammatory cytokines such as interleukin 10 – but this difference was lost with age. Levels of macrophages, which promote inflammation, increased with age in women but not in men.

Dr Maria Luisa Barcena De Arellano, scientific researcher, Institute of Gender Medicine, Charité University Medicine Berlin, Germany, said: “Our study provides a molecular explanation for the increased incidence of cardiovascular diseases in older women.”

“We found that the hearts of older women have reduced expression of antioxidant proteins and proteins that are important for mitochondrial function,” she continued. “This may lead to the increased inflammation we observed in older women. Inflammation is known to contribute to cardiovascular disease.”

Dr Barcena De Arellano said that in young women, oestrogen may protect or improve the function of the mitochondria and keep inflammation down. She said: “We have previously shown that oestrogen improves the expression of mitochondrial proteins and antioxidant proteins, and decreases oxidative stress. We think that the fall in oestrogen with menopause contributes to mitochondrial dysfunction.”

She added that hormone replacement therapy is taken by some women to boost oestrogen levels and reduce the risk of heart disease, but it may not be appropriate for everyone.

Dr Barcena De Arellano said: “Our study suggests that a new drug could be developed which increases the expression of mitochondrial proteins. This could improve mitochondrial function, reduce inflammation, and help to prevent cardiovascular disease in older women.”

ENDS

Notes to editor

Authors: ESC Press Office

Tel: +33 (0)4 89 87 24 83

Mob: +33 (0)6 24 71 28 96

Email: press@escardio.org

SOURCES OF FUNDING: The study was sponsored by DZHK (German Centre for Cardiovascular Research, partner site Berlin).

DISCLOSURES: None.

References and notes

(1) The abstract ‘Sex differences in age-related AMPK-Sirt1 axis alteration in human heart’ will be presented during the Poster session: Basic Science – Cardiac Biology and Physiology which takes place on 21 April from 08:30 to 16:30 CEST in the Poster Area..

(2) EUGenMed Cardiovascular Clinical Study Group, Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37(1):24–34.

About Frontiers in CardioVascular Biology

Frontiers in CardioVascular Biology (FCVB) is a comprehensive basic science conference organised every two years by the ESC Council on Basic Cardiovascular Science, whose mission is to enhance the importance of basic science to clinical cardiology. FCVB is organised in collaboration with 12 European cardiovascular science societies.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

Information for journalists attending FCVB 2018

FCVB 2018 will be held from 20 to 22 April at the Austria Centre Vienna in Vienna, Austria. The full scientific programme is available here

  • To register on-site please bring avalid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related, or referring to a previous ESC Event).
  • Press registration is not available to industry or its public relations representatives, event management, marketing or communications representatives.